| # | Drug | Count |
|---|---|---|
| 0 | AFLIBERCEPT | 10 |
| 1 | RANIBIZUMAB | 6 |
| 2 | BROLUCIZUMAB | 5 |
| 3 | FARICIMAB | 5 |
| 4 | BEVACIZUMAB | 3 |
| 5 | CYCLOPHOSPHAMIDE | 3 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 3 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 3 |
| 8 | DOCETAXEL | 2 |
| 9 | DOCETAXEL ANHYDROUS | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BROLUCIZUMAB | 5 | 0.0014 |
| 1 | FARICIMAB | 5 | 0.0006 |
| 2 | AFLIBERCEPT | 10 | 0.0003 |
| 3 | FOSCARNET SODIUM | 1 | 0.0002 |
| 4 | RANIBIZUMAB | 6 | 0.0002 |
| 5 | OFLOXACIN OPHTHALMIC SOLUTION USP, 0.3% | 1 | 0.0001 |
| 6 | OFLOXACIN OTIC SOLUTION | 1 | 0.0001 |
| 7 | OFLOXACIN OTIC | 1 | 0.0001 |
| 8 | OFLOXACIN | 1 | 0.0001 |
| 9 | PYRAZINAMIDE | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Quinolone Antimicrobial [EPC] | 1 | 0.0001 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 15 | 0.0001 |
| 2 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 1 | 0.0001 |
| 3 | Antimycobacterial [EPC] | 1 | 0.0000 |
| 4 | Ester Local Anesthetic [EPC] | 1 | 0.0000 |
| 5 | Non-Standardized Chemical Allergen [EPC] | 1 | 0.0000 |
| 6 | Alkylating Drug [EPC] | 3 | 0.0000 |
| 7 | Microtubule Inhibitor [EPC] | 2 | 0.0000 |
| 8 | Amide Local Anesthetic [EPC] | 1 | 0.0000 |
| 9 | Antiarrhythmic [EPC] | 1 | 0.0000 |